Text4baby firm launches mobile diabetes program

Share this article:
Text4baby firm launches mobile diabetes program
Text4baby firm launches mobile diabetes program

Mobile health firm Voxiva, which was part of the innovative Johnson & Johnson-supported text4baby program, is looking to tackle type 2 diabetes with Care4Life.

The mobile health program includes a personalized patient portal and may also be expanded to include an app (feeback from three test sites will be used to tweak the project), but the text element is the key driver -- in addition to delivering advice and education information, users can also send information about glucose levels and doctor appointments through their phones and into the patient profile. Text messaging rates are the only cost linked to the initiative.

Marketing manager Emilia Guasconi said the messaging channel has a strong track record. “The beauty is the simplicity of it. It's much easier than having to download an app. You don't need to have a smartphone,” she explained. Guasconi said that although an app could be developed, the power to reach underserved patients is based on texting "because people who are covered under Medicaid are actually high users of text messaging.”

Among the stats supporting optimism: a text4baby poll about flu shots had a 30% response rate, and 73% who answered that they weren't getting shots explained why when they received a message asking “Why not?” The organization's internal data also shows that 64% of text4baby participants used text messages like an archive, drawing on texted advice or tips to ask questions at doctor's appointments. Voxiva's compiled research also found that 99% of text messages are read, usually within three minutes of receipt.

“You can really encourage behavior change through text messaging,” Guasconi said.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...